Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BaroFeron versus Betaferon repeat-dose phase 1 study in healthy volunteers
NL-OMON32092Phase 1Active, not recruiting
- Sponsor
- BaroFold
- Start
- Jun 2008
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of BaroFeron and interferon beta-1a in multiple sclerosis (MS) (7 arms), sponsored by BaroFold. Primary endpoints: Adverse events, Pharmacokinetics and 1 more. Started Jun 2008; status: active, not recruiting.
02
Drugs
BaroFeroninterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON32092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32092.